Elicera Therapeutics AB (ELIC) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.156x

Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has a cash flow conversion efficiency ratio of -0.156x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.74 Million ≈ $-509.90K USD) by net assets (Skr30.33 Million ≈ $3.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Elicera Therapeutics AB for the company's overall valuation and market capitalisation.

Elicera Therapeutics AB - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Elicera Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Elicera Therapeutics AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Elicera Therapeutics AB ranked by their cash flow conversion efficiency. Explore ELIC cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Qyou Media Inc V:QYOU	0.060x
BTC Digital Ltd. NASDAQ:BTCT	-0.007x
Denali Capital Acquisition Corp. Class A Ordinary Shares NASDAQ:DECA	0.008x
Euromedis Groupe SA PA:ALEMG	0.048x
Horizon Petroleum Ltd V:HPL	0.257x
Brightline Interactive, Inc. NASDAQ:BTLN	-0.534x
ASTORY Co.Ltd KQ:241840	-0.064x
TIALIS ESSENTIAL IT PLC F:U6M	N/A

Annual Cash Flow Conversion Efficiency for Elicera Therapeutics AB (2017–2024)

The table below shows the annual cash flow conversion efficiency of Elicera Therapeutics AB from 2017 to 2024. View ELIC live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr20.77 Million ≈ $2.24 Million	Skr-23.46 Million ≈ $-2.53 Million	-1.130x	-24.16%
2023-12-31	Skr16.40 Million ≈ $1.77 Million	Skr-14.92 Million ≈ $-1.61 Million	-0.910x	-248.18%
2022-12-31	Skr32.80 Million ≈ $3.53 Million	Skr-8.57 Million ≈ $-922.36K	-0.261x	+4.50%
2021-12-31	Skr52.24 Million ≈ $5.62 Million	Skr-14.29 Million ≈ $-1.54 Million	-0.274x	-209.39%
2020-12-31	Skr10.24 Million ≈ $1.10 Million	Skr-905.25K ≈ $-97.42K	-0.088x	+77.29%
2019-12-31	Skr614.10K ≈ $66.09K	Skr-239.16K ≈ $-25.74K	-0.389x	-31.11%
2018-12-31	Skr805.16K ≈ $86.65K	Skr-239.16K ≈ $-25.74K	-0.297x	-0.44%
2017-12-31	Skr808.69K ≈ $87.03K	Skr-239.16K ≈ $-25.74K	-0.296x	--

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$14.55 Million

Skr135.17 Million SEK

Market Cap Rank

#26163 Global

#538 in Sweden

Share Price

Skr2.79

Change (1 day)

-0.71%

52-Week Range

Skr2.30 - Skr7.90

All Time High

Skr8.56